Aflac Incorporated (NYSE:AFL) is included among the 15 Overlooked Dividend Stocks to Buy Right Now.
Photo by
Dan Dennis on
Unsplash
On November 7, Evercore ISI analyst Thomas Gallagher raised the firm’s price target on Aflac Incorporated (NYSE:AFL) to $111 from $110 while maintaining an Underperform rating following the company’s third-quarter results, according to a report by The Fly.
Aflac Incorporated (NYSE:AFL) reported total revenue of $4.7 billion in Q3 2025, up from $2.9 billion in the same quarter last year. The increase was largely driven by net investment gains of $275 million this quarter, compared with net investment losses of $1.4 billion in Q3 2024. Net earnings came in at $1.6 billion, or $3.08 per diluted share, versus a net loss of $93 million, or $0.17 per share, a year earlier.
In the earnings release, Senior EVP and CFO Max Broden outlined guidance for 2025, projecting that the benefit ratio in Japan will range from 58% to 60% while the expense ratio is expected at the lower end of the 20%–23% range. He also noted that Aflac Japan’s pre-tax profit margin is anticipated to fall between 35% and 38%.
Aflac Incorporated (NYSE:AFL) provides supplemental insurance products, including accident, cancer, critical illness, and life coverage, paying cash benefits directly to policyholders to help cover medical and other expenses that primary health insurance may not fully address.
While we acknowledge the potential of AFL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Best Dividend Growth Stocks to Buy Now and 15 Best DRIP Stocks to Own Right Now.
Disclosure: None.